Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 03 - 18 tags : Trial save search
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Lordstown Motors Corp. (RIDE) Investors with $100K+ Losses to Contact Firm Now: Securities Fraud Case Filed
Published: 2021-03-18 (Crawled : 00:00) - prnewswire.com
RIDE | $2.2 2.33% 2.71% 1.4M
|
Consumer Durables
|
| O: -0.23%
H: 4.47%
C: 2.47%
trial
Worldwide Industrial Microbiology Industry to 2030 - Technological Advancements for Commercial Quality Assurance are Driving Growth
Published: 2021-03-18 (Crawled : 20:00) - prnewswire.com
QGEN | $39.47 0.61% 0.0% 950K
|
Health Technology
|
| O: 1.93%
H: 2.28%
C: 1.77%
DHR | $236.36 -1.27% 0.0% 4.2M
|
Health Technology
|
| O: 0.39%
H: 2.17%
C: 1.96%
CRL | $227.55 -1.1% 0.0% 710K
|
Commercial Services
|
| O: -0.1%
H: 1.4%
C: -0.45%
BIO | News | $281.02 -3.38% -0.36% 370K
|
Health Technology
|
| O: 0.11%
H: 0.99%
C: -0.31%
BDX | $233.15 0.41% 0.15% 890K
|
Health Technology
|
| O: 0.31%
H: 0.58%
C: -0.38%
MMM | $91.48 0.57% 0.0% 3M
|
Producer Manufacturing
|
| O: -0.21%
H: 0.21%
C: -0.99%
QGEN | $39.47 0.61% 0.0% 950K
|
Health Technology
|
| O: 1.93%
H: 2.28%
C: 1.77%
growth trial commercialization
Drug Trials Snapshots: ZULRESSO
Published: 2021-03-18 (Crawled : 18:38) - fda.gov
SAGE | $13.03 3.66% 3.53% 1.8M
|
Health Technology
|
| O: -1.24%
H: 3.04%
C: -3.76%
drug trial
Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100
Published: 2021-03-18 (Crawled : 18:00) - biospace.com/
DYAI A | $1.605 -4.46% -4.67% 37K
|
Health Technology
|
| O: 6.49%
H: 2.16%
C: -6.68%
vaccine trial sars-cov-2
BOA™ Biomedical's GARNET™ therapeutic product begins First in Human clinical trial
Published: 2021-03-18 (Crawled : 17:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.35%
H: 0.8%
C: 0.16%
trial
Hepion PharmaceuticalsENDRA Life Sciences and Hepion Pharmaceuticals Partner to Drive Efficiencies in NASH Clinical Trials
Published: 2021-03-18 (Crawled : 17:00) - biospace.com/
HEPA | $2.1 -1.41% -1.43% 28K
|
Health Technology
|
| O: 1.64%
H: 1.07%
C: -6.08%
NDRA | $0.2334 1.13% 1.11% 58K
|
Health Technology
|
| O: 2.86%
H: 7.64%
C: -4.86%
clinical trials life science nash trial
Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate XL092 and Avelumab in Various Forms of Locally Advanced or Metastatic Urothelial Carcinoma
Published: 2021-03-18 (Crawled : 17:00) - biospace.com/
EXEL | $22.47 -1.75% -1.78% 2.6M
|
Health Technology
|
| O: -0.99%
H: 2.66%
C: -0.26%
collaboration trial germany urothelial carcinoma
Drug Trial Snapshot: TEGSEDI
Published: 2021-03-18 (Crawled : 16:03) - fda.gov
IONS | $40.81 -0.24% -0.25% 990K
|
Health Technology
|
| O: -0.66%
H: 2.34%
C: -0.38%
drug trial
Wake Research Earns Recognition For Novavax COVID-19 Vaccine Trial, And As Top Clinical Service Provider Of 2021
Published: 2021-03-18 (Crawled : 15:00) - prnewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.35%
H: 0.8%
C: 0.16%
covid vaccine research trial
Drug Trial Snapshot: DAURISMO
Published: 2021-03-18 (Crawled : 15:00) - fda.gov
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.73%
H: 1.24%
C: 0.68%
drug trial
Sorrento Announces First Patient Treated in Phase IB AL Amyloidosis Trial with STI-6129, an Anti-CD38 Antibody-Drug Conjugate
Published: 2021-03-18 (Crawled : 13:30) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: -1.2%
H: 2.83%
C: -4.35%
antibody drug trial als
Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ-252 as a Potential Treatment for Vitiligo
Published: 2021-03-18 (Crawled : 13:30) - globenewswire.com
ARQT A | $9.45 -7.81% -8.47% 2.9M
|
Health Technology
|
| O: -1.11%
H: 1.16%
C: -5.28%
treatment phase 2 potential trial phase 2b enroll
PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief
Published: 2021-03-18 (Crawled : 13:30) - globenewswire.com
PRFX | News 0 d | $0.871 -4.38% -4.58% 38K
|
Health Technology
|
| O: 1.06%
H: 1.03%
C: -12.74%
pain relief phase 3 trial
Cytokinetics Announces Secondary Analysis From GALACTIC-HF to Be Presented in Late Breaking Clinical Trial Session at American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21)
Published: 2021-03-18 (Crawled : 12:00) - globenewswire.com
CYTK | $67.0 -1.37% -1.39% 890K
|
Health Technology
|
| O: 0.12%
H: 0.43%
C: -5.37%
cardiology cardio trial
BTBT 5-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Notifies Bit Digital (BTBT) Investors of Expanded Class Period, Investors with $100K+ Losses Should Contact the Firm Now
Published: 2021-03-18 (Crawled : 04:00) - prnewswire.com
BTBT | $1.925 6.35% 5.97% 4.4M
|
Finance
|
| O: -1.46%
H: 4.04%
C: -7.0%
trial
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Lordstown Motors Corp. (RIDE) For Possible Securities Fraud, SEC Inquiry and Internal Review Opened, Investors with Losses Should Contact Firm's Attorneys Now
Published: 2021-03-18 (Crawled : 04:00) - prnewswire.com
RIDE | $2.2 2.33% 2.71% 1.4M
|
Consumer Durables
|
| O: -8.22%
H: 1.66%
C: -6.06%
trial
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.